<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">healthcare</journal-id><journal-title-group><journal-title xml:lang="ru">Здравоохранение. Healthcare</journal-title><trans-title-group xml:lang="en"><trans-title>Healthcare</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1027-7218</issn><publisher><publisher-name>Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Health Economics</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">healthcare-168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group></article-categories><title-group><article-title>Синдром активации тучных клеток: возможности фармакотерапии</article-title><trans-title-group xml:lang="en"><trans-title>Mast cell activation syndrome: possibilities for pharmacotherapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Василевский</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasilevsky</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Василевский Игорь Вениаминович - д. м. н., профессор кафедры клинической фармакологии</p><p>пр. Дзержинского, 83, 220083, г. Минск, БеларусьСл.тел. +375 17 282-91-32 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Белорусский государственный медицинский университет</institution><country>Belarus</country></aff><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>27</day><month>09</month><year>2025</year></pub-date><volume>0</volume><issue>12</issue><fpage>24</fpage><lpage>35</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Василевский И.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Василевский И.В.</copyright-holder><copyright-holder xml:lang="en">Vasilevsky I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://healthcare.ejournal.by/jour/article/view/168">https://healthcare.ejournal.by/jour/article/view/168</self-uri><abstract><p>Прошло около 150 лет с тех пор, как Пауль Эрлих впервые описал тучные клетки, но и в наше время продолжается углубленное изучение функций тучных клеток, детализация участия их как в сохранении здоровья, так и выяснении их роли при различных патологических состояниях. Современные достижения в исследованиях тучных клеток укрепили понимание того, что тучные клетки обладают уникальными иммунными функциями, более глубокое изучение которых окажет большое влияние на состояние здоровья человека. Появляется все больше доказательств их участия в патогенезе не только аллергических, но и других заболеваний, включая инфекцию SARS-CoV-2, псориаз, миалгический энцефаломиелит, рассеянный склероз, заболевания системы пищеварения, ревматоидный артрит, интерстициальный цистит, развитие опухолей, сердечно-сосудистых заболеваний и другой патологии, связанной с хроническим воспалением. Современные данные о функции тучных клеток, первичной и вторичной дисфункции их, включая синдром активации тучных клеток, требуют нового аналитического подхода - нового мировоззрения. В литературе последних лет активно обсуждается потенциал тучных клеток и их многочисленных медиаторов в качестве терапевтических мишеней и биомаркеров тяжести заболеваний и результатов лечения, что согласуется с принципами прецизионной медицины.</p></abstract><trans-abstract xml:lang="en"><p>About a century and a half has passed since Paul Ehrlich first described mast cells, but even today, in-depth study of the functions of mast cells continues, detailing their participation both in maintaining health and elucidating their role in various pathological conditions. Modern advances in mast cell research have strengthened the understanding that mast cells have unique immune functions, a better understanding of which will have a major impact on human health. There is increasing evidence of their participation in the pathogenesis of not only allergic, but also other diseases, including SARS-CoV-2 infection, psoriasis, myalgic encephalomyelitis, multiple sclerosis, diseases of the digestive system, rheumatoid arthritis, interstitial cystitis, tumor development, cardiovascular vascular diseases and other pathologies associated with chronic inflammation. Modem data on the function of mast cells, their primary and secondary dysfunction, including mast cell activation syndrome, require a new analytical approach - a new worldview. The potential of mast cells and their numerous mediators as therapeutic targets and biomarkers of disease severity and treatment outcome has been actively discussed in the recent literature, which is consistent with the principles of precision medicine.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тучные клетки</kwd><kwd>первичная и вторичная дисфункция тучных клеток</kwd><kwd>синдром активации тучных клеток</kwd><kwd>рациональная фармакотерапия</kwd><kwd>прецизионная медицина</kwd></kwd-group><kwd-group xml:lang="en"><kwd>mast cells</kwd><kwd>primary and secondary mast cell dysfunction</kwd><kwd>mast cell activation syndrome</kwd><kwd>rational pharmacotherapy</kwd><kwd>precision medicine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cookson H., Grattan C. An update on mast cell disorders. Clin. Med. (Lond). 2016; 16: 580-3.</mixed-citation><mixed-citation xml:lang="en">Cookson H., Grattan C. An update on mast cell disorders. Clin. Med. (Lond). 2016; 16: 580-3.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Moon T. C., Befus A. D., Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front. Immunol. 2014: 5: 569.</mixed-citation><mixed-citation xml:lang="en">Moon T. C., Befus A. D., Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front. Immunol. 2014: 5: 569.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vliagoftis H., Befus A. D. Rapidly changing perspectives about mast cells at mucosal surfaces. Immunol. Rev. 2005; 206: 190 203.</mixed-citation><mixed-citation xml:lang="en">Vliagoftis H., Befus A. D. Rapidly changing perspectives about mast cells at mucosal surfaces. Immunol. Rev. 2005; 206: 190 203.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mekori Y. A., Metcalfe D. D. Mast cells in innate immunity. Immunol. Rev. 2000; 173: 131-40.</mixed-citation><mixed-citation xml:lang="en">Mekori Y. A., Metcalfe D. D. Mast cells in innate immunity. Immunol. Rev. 2000; 173: 131-40.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Akin C. Mast cell activation disorders. J. Allergy Clin. Immunol. Pract. 2014; 2: 252-7.e1.</mixed-citation><mixed-citation xml:lang="en">Akin C. Mast cell activation disorders. J. Allergy Clin. Immunol. Pract. 2014; 2: 252-7.e1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yu L. C., Perdue M. H. Role of mast cells in intestinal mucosal function:studies in models of hypersensitivity and stress. Immunol. Rev. 2001; 179: 61 -73.</mixed-citation><mixed-citation xml:lang="en">Yu L. C., Perdue M. H. Role of mast cells in intestinal mucosal function:studies in models of hypersensitivity and stress. Immunol. Rev. 2001; 179: 61 -73.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bischoff S. C. Physiological and pathophysiological functions of intestinal mast cells. Semin. Immunopathol. 2009: 31: 185 205.</mixed-citation><mixed-citation xml:lang="en">Bischoff S. C. Physiological and pathophysiological functions of intestinal mast cells. Semin. Immunopathol. 2009: 31: 185 205.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Varricchi G., De Paulis A., Marone G., Galli S. J. Future needs in mast cell biology. Int. J. Mol. Sci. 2019; 20: 4397.</mixed-citation><mixed-citation xml:lang="en">Varricchi G., De Paulis A., Marone G., Galli S. J. Future needs in mast cell biology. Int. J. Mol. Sci. 2019; 20: 4397.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Theoharides T., Tsilioni I., Ren H. Recent advances in our understanding of mast cell activation: or should it be mast cell mediator disorders? Expert Rev. Clin. Immunol. 2019; 15: 639 56.</mixed-citation><mixed-citation xml:lang="en">Theoharides T., Tsilioni I., Ren H. Recent advances in our understanding of mast cell activation: or should it be mast cell mediator disorders? Expert Rev. Clin. Immunol. 2019; 15: 639 56.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rivellese F., Rossi F. W., Galdiero M. R. et al. Mast cells in early rheumatoid arthritis. Int. J. Mol. Med. 2019; 20: 1-13.</mixed-citation><mixed-citation xml:lang="en">Rivellese F., Rossi F. W., Galdiero M. R. et al. Mast cells in early rheumatoid arthritis. Int. J. Mol. Med. 2019; 20: 1-13.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ragipoglu D., Dudeck A., Haffner-Luntzer M. et al. The role of mast cells in bone metabolism and bone disorders. Front. Immunol. 2020: 11: 163.</mixed-citation><mixed-citation xml:lang="en">Ragipoglu D., Dudeck A., Haffner-Luntzer M. et al. The role of mast cells in bone metabolism and bone disorders. Front. Immunol. 2020: 11: 163.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sprinzl B., Greiner G., Uyanik G. et al. Genetic regulation of tryptase production and clinical impact: hereditary alpha tryptasemia, mastocytosis and beyond. Int. J. Mol. Sci. 2021: 22: 2458.</mixed-citation><mixed-citation xml:lang="en">Sprinzl B., Greiner G., Uyanik G. et al. Genetic regulation of tryptase production and clinical impact: hereditary alpha tryptasemia, mastocytosis and beyond. Int. J. Mol. Sci. 2021: 22: 2458.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bagher M., Larsson-Callerfelt A. K., Rosmark O. et al. Mast cells and mast cell tryptase enhance migration of human lung fibroblasts through protease-activated receptor 2. Cell. Commun. Signal. 2018; 16: 59.</mixed-citation><mixed-citation xml:lang="en">Bagher M., Larsson-Callerfelt A. K., Rosmark O. et al. Mast cells and mast cell tryptase enhance migration of human lung fibroblasts through protease-activated receptor 2. Cell. Commun. Signal. 2018; 16: 59.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Desai A., Jung M. Y., Olivera A. etal. IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J. Allergy Clin. Immunol. 2016; 137: 1863 71.</mixed-citation><mixed-citation xml:lang="en">Desai A., Jung M. Y., Olivera A. etal. IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J. Allergy Clin. Immunol. 2016; 137: 1863 71.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hallgren J., Pejler G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J. 2006; 273: 1871 95.</mixed-citation><mixed-citation xml:lang="en">Hallgren J., Pejler G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J. 2006; 273: 1871 95.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz L. B., Min H. K., Ren S. et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J. Immunol. 2003; 170: 5667-73.</mixed-citation><mixed-citation xml:lang="en">Schwartz L. B., Min H. K., Ren S. et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J. Immunol. 2003; 170: 5667-73.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz L. B. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol. Allergy Clin. North Am. 2006; 26: 451-63.</mixed-citation><mixed-citation xml:lang="en">Schwartz L. B. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol. Allergy Clin. North Am. 2006; 26: 451-63.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cildir G., Pant H., Lopez A. F., Tergaonkar V. The transcriptional program, functional heterogeneity, and clinical targeting of mast cells. J. ExpMed. 2017; 214 (9): 2491-506 .</mixed-citation><mixed-citation xml:lang="en">Cildir G., Pant H., Lopez A. F., Tergaonkar V. The transcriptional program, functional heterogeneity, and clinical targeting of mast cells. J. ExpMed. 2017; 214 (9): 2491-506 .</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ustun C., Arock M., Kluin-Nelemans H. C. et al. Advanced systemic mastocytosis: From molecular and genetic progress to clinical practice. Haematologica. 2016; 101: 1133 43.</mixed-citation><mixed-citation xml:lang="en">Ustun C., Arock M., Kluin-Nelemans H. C. et al. Advanced systemic mastocytosis: From molecular and genetic progress to clinical practice. Haematologica. 2016; 101: 1133 43.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Valent P., Akin C., Hartmann K. et al. Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future. Cancer Res. 2017: 77: 1261…70.</mixed-citation><mixed-citation xml:lang="en">Valent P., Akin C., Hartmann K. et al. Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future. Cancer Res. 2017: 77: 1261…70.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Voehringer D. Protective and pathological roles of mast cells and basophils. Nat. Rev. Immunol. 2013; 13: 362 75.</mixed-citation><mixed-citation xml:lang="en">Voehringer D. Protective and pathological roles of mast cells and basophils. Nat. Rev. Immunol. 2013; 13: 362 75.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Galli S. J., Borregaard N., Wynn T. A.… Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils. Nat. Immunol. 2011; 12:10354 5 44.</mixed-citation><mixed-citation xml:lang="en">Galli S. J., Borregaard N., Wynn T. A.… Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils. Nat. Immunol. 2011; 12:10354 5 44.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wernersson S., Pejler G. Mast cell secretory granules: Armed for battle. Nat. Rev. Immunol. 2014; 14: 478 94.</mixed-citation><mixed-citation xml:lang="en">Wernersson S., Pejler G. Mast cell secretory granules: Armed for battle. Nat. Rev. Immunol. 2014; 14: 478 94.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Abraham S. N., St. John A. L. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 2010; 10: 440 52.</mixed-citation><mixed-citation xml:lang="en">Abraham S. N., St. John A. L. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 2010; 10: 440 52.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lam H. Y., Tergaonkar V., Kumar A. P., Ahn K. S. Mast cells: Therapeutic targets for COVID-19 and beyond. IUBMBLife. 2021; 73 (11): 1278 92.</mixed-citation><mixed-citation xml:lang="en">Lam H. Y., Tergaonkar V., Kumar A. P., Ahn K. S. Mast cells: Therapeutic targets for COVID-19 and beyond. IUBMBLife. 2021; 73 (11): 1278 92.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Galli S. J., Gaudenzio N., Tsai M. Mast cells in inflammation and disease: recent progress and ongoing concems. Ann. Rev. Immunol. 2020; 38: 49 77.</mixed-citation><mixed-citation xml:lang="en">Galli S. J., Gaudenzio N., Tsai M. Mast cells in inflammation and disease: recent progress and ongoing concems. Ann. Rev. Immunol. 2020; 38: 49 77.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Weiler C. R., Austen K. F., Akin C. et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. J. Allergy Clinimmunol. 2019; 144 (4): 883 96.</mixed-citation><mixed-citation xml:lang="en">Weiler C. R., Austen K. F., Akin C. et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. J. Allergy Clinimmunol. 2019; 144 (4): 883 96.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Valent P. Mast cell activation syndromes:definition and classification. Allergy. 2013; 68: 417 24.</mixed-citation><mixed-citation xml:lang="en">Valent P. Mast cell activation syndromes:definition and classification. Allergy. 2013; 68: 417 24.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Lee M. J, Akin C. Mast cell activation syndromes. Ann. Allergy Asthma Immunol. 2013; 111: 5 8.</mixed-citation><mixed-citation xml:lang="en">Lee M. J, Akin C. Mast cell activation syndromes. Ann. Allergy Asthma Immunol. 2013; 111: 5 8.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Picard M., Giavina-Bianchi P., Mezzano V., Castells M. Expanding spectrum of mast cell activation disorders:monoclonal and idiopathic mast cell activation syndromes. Clin. Ther. 2013; 35: 548 62.</mixed-citation><mixed-citation xml:lang="en">Picard M., Giavina-Bianchi P., Mezzano V., Castells M. Expanding spectrum of mast cell activation disorders:monoclonal and idiopathic mast cell activation syndromes. Clin. Ther. 2013; 35: 548 62.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Akin C. Mast cell activation syndromes. J. Allergy Clin. Immunol. 2017: 140: 349 55.</mixed-citation><mixed-citation xml:lang="en">Akin C. Mast cell activation syndromes. J. Allergy Clin. Immunol. 2017: 140: 349 55.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Frieri M. Mast cell activation syndrome. Clin. Rev. Allergy Immunol. 2018; 54: 353 65.</mixed-citation><mixed-citation xml:lang="en">Frieri M. Mast cell activation syndrome. Clin. Rev. Allergy Immunol. 2018; 54: 353 65.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Valent P., Akin C., Arock M. et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int. Arch. Allergy Immunol. 2012; 157: 215 25.</mixed-citation><mixed-citation xml:lang="en">Valent P., Akin C., Arock M. et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int. Arch. Allergy Immunol. 2012; 157: 215 25.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kritas S. K., Ronconi G., Caraffa Al. et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J. Biol. Regul. Home ost Agents 2020; 34 (1): 9 14.</mixed-citation><mixed-citation xml:lang="en">Kritas S. K., Ronconi G., Caraffa Al. et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J. Biol. Regul. Home ost Agents 2020; 34 (1): 9 14.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Motta J. J., Miggiolaro A. F., Nagashima S. et al. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Front. Immunol. 2020; 11: 574862.</mixed-citation><mixed-citation xml:lang="en">Motta J. J., Miggiolaro A. F., Nagashima S. et al. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Front. Immunol. 2020; 11: 574862.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Z., Ren L., Zhang L., et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020; 27: 883 890.e2.</mixed-citation><mixed-citation xml:lang="en">Zhou Z., Ren L., Zhang L., et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020; 27: 883 890.e2.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Gebremeskel S., Schanin J., Coyle K. M. et al. Mast cell and eosinophil activation are associated with COVID-19 and TLR-mediated viral inflammation: implications for an anti-siglec-8 antibody. Front. Immunol. 2021; 12: 1-12.</mixed-citation><mixed-citation xml:lang="en">Gebremeskel S., Schanin J., Coyle K. M. et al. Mast cell and eosinophil activation are associated with COVID-19 and TLR-mediated viral inflammation: implications for an anti-siglec-8 antibody. Front. Immunol. 2021; 12: 1-12.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Tan J., Anderson D. E., Rathore A. P. et al. Signatures of mast cell activation are associated with severe COVID-19. medRxiv. 2021: 21255594.</mixed-citation><mixed-citation xml:lang="en">Tan J., Anderson D. E., Rathore A. P. et al. Signatures of mast cell activation are associated with severe COVID-19. medRxiv. 2021: 21255594.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Y., Chen G. Mast cell and autoimmune diseases. Mediators Inflamm. 2015; 246126.</mixed-citation><mixed-citation xml:lang="en">Xu Y., Chen G. Mast cell and autoimmune diseases. Mediators Inflamm. 2015; 246126.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Tetlow L., Woolley D. Mast Cells, Cytokines, and Metalloproteinases at the Rheumatoid Lesion: Dual. Immunolocalisation Studies. Ann. Rheum. Dis. 1995; 54 (11): 896 903.</mixed-citation><mixed-citation xml:lang="en">Tetlow L., Woolley D. Mast Cells, Cytokines, and Metalloproteinases at the Rheumatoid Lesion: Dual. Immunolocalisation Studies. Ann. Rheum. Dis. 1995; 54 (11): 896 903.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Gotis-Graham I., Smith M. D., Parker A., McNeil H. P. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann. Rheum. Dis. 1998; 57 (11): 664 71.</mixed-citation><mixed-citation xml:lang="en">Gotis-Graham I., Smith M. D., Parker A., McNeil H. P. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann. Rheum. Dis. 1998; 57 (11): 664 71.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Kim K. W., Kim B. M., Won J. Y. et al. Regulation of Osteoclastogenesis by Mast Cell in Rheumatoid Arthritis. Arthritis Res. Ther. 2021; 23 (1): 124.</mixed-citation><mixed-citation xml:lang="en">Kim K. W., Kim B. M., Won J. Y. et al. Regulation of Osteoclastogenesis by Mast Cell in Rheumatoid Arthritis. Arthritis Res. Ther. 2021; 23 (1): 124.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Rivellese F., Mauro D., Nerviani A. et al. Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production. Ann. Rheum. Dis. 2018; 77 (12): 1773 81.</mixed-citation><mixed-citation xml:lang="en">Rivellese F., Mauro D., Nerviani A. et al. Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production. Ann. Rheum. Dis. 2018; 77 (12): 1773 81.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Василевский И. В. Роль тучных клеток при заболеваниях желудочно-кишечного тракта у детей. Материалы 28 Конгресса детских гастроэнтерологов России и стран СНГ «Актуальные проблемы абдоминальной патологии у детей». Москва, 23 -25 марта 2021 г. М.: ИД «МЕДПРАКТИКА-М»; 2021. С. 13 -15.</mixed-citation><mixed-citation xml:lang="en">Vasilevsky I.V. The role of mast cells in diseases of the gastrointestinal tract in children. Materials of the 28th Congress of Pediatric Gastroenterologists of Russia and the CIS Countries «Current Problems of Abdominal Pathology in Children». Moscow, March 23-25, 2021. M.: ID «MEDPRACTIKA-M», 2021. p. 13 -15. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Bischoff S. C., Kramer S. Human mast cells, bacteria, and intestinal immunity. Immunol. Rev. 2007; 217: 329 -37.</mixed-citation><mixed-citation xml:lang="en">Bischoff S. C., Kramer S. Human mast cells, bacteria, and intestinal immunity. Immunol. Rev. 2007; 217: 329 -37.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Василевский И. В. Современные подходы к пониманию сущности эозинофильного эзофагита. Медицинские новости. 2021; 8: 27--32.</mixed-citation><mixed-citation xml:lang="en">Vasilevsky I. V. Modern approaches to understanding the essence of eosinophilic esophagitis. Meditsinskie novosti. 2021; 8: 27 32. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Василевский И. В. Молекулярно-патофизиологические механизмы возникновения аллергического эзофагита. Материалы Юбилейного XXX Конгресса детских гастроэнтерологов России и стран СНГ «Актуальные проблемы абдоминальной патологии у детей». М.: ИД «Медпрактика-М»; 2023. С. 119 -121.</mixed-citation><mixed-citation xml:lang="en">Vasilevsky I. V. Molecular pathophysiological mechanisms of allergic esophagitis. Materials of the Anniversary XXX Congress of Pediatric Gastroenterologists of Russia and the CIS Countries «Current Problems of Abdominal Pathology in Children». M.: Publishing House «Medpraktika-M», 2023. p. 119 21. [(in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Yeom J. S., Buchowski J. M., Kim H. J. et al. Risk of vertebral artery injury: comparison between C1-C2 transarticular and C2 pedicle screws. Spine J. 2013; 13 (7): 775 85.</mixed-citation><mixed-citation xml:lang="en">Yeom J. S., Buchowski J. M., Kim H. J. et al. Risk of vertebral artery injury: comparison between C1-C2 transarticular and C2 pedicle screws. Spine J. 2013; 13 (7): 775 85.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180 (7): 934 43.</mixed-citation><mixed-citation xml:lang="en">Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180 (7): 934 43.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Czamy J., Lange M., Lugowska-Umer H., Nowicki R. J. Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Postepy Dermatol. Alergol. 2018; 35 (6): 541-5.</mixed-citation><mixed-citation xml:lang="en">Czamy J., Lange M., Lugowska-Umer H., Nowicki R. J. Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Postepy Dermatol. Alergol. 2018; 35 (6): 541-5.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Siebenhaar F., Sander B., Ho L.H. et al. Development and validation ofthe mastocytosis activity score. Allergy. 2018; 73 (7): 1489 -96.</mixed-citation><mixed-citation xml:lang="en">Siebenhaar F., Sander B., Ho L.H. et al. Development and validation ofthe mastocytosis activity score. Allergy. 2018; 73 (7): 1489 -96.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Kiwamoto T., Kawasaki N., Paulson J. C., Bochner B. S. Siglec-8 as a drugable target to treat eosinophil and mast cellassociated conditions. Pharmacol. Ther. 2012: 135: 32736.</mixed-citation><mixed-citation xml:lang="en">Kiwamoto T., Kawasaki N., Paulson J. C., Bochner B. S. Siglec-8 as a drugable target to treat eosinophil and mast cellassociated conditions. Pharmacol. Ther. 2012: 135: 32736.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Mizrahi S., Gibbs B.F., Karra L. et al. Siglec-7 is an inhibitory receptor on human mast cells and basophils. J. Allergy Clin. Immunol. 2014; 134: 230 -233.e3.</mixed-citation><mixed-citation xml:lang="en">Mizrahi S., Gibbs B.F., Karra L. et al. Siglec-7 is an inhibitory receptor on human mast cells and basophils. J. Allergy Clin. Immunol. 2014; 134: 230 -233.e3.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Burchett J. R., Dailey J. M., Kee S. A. et al. Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing. Cells. 2022; 11: 3031.</mixed-citation><mixed-citation xml:lang="en">Burchett J. R., Dailey J. M., Kee S. A. et al. Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing. Cells. 2022; 11: 3031.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Baran J., Sobiepanek A., Mazurkiewicz-Pisarek A. et al. Mast cells as a target - a comprehensive review ofrecent therapeutic approaches. Cells. 2023; 12 (8): 1187.</mixed-citation><mixed-citation xml:lang="en">Baran J., Sobiepanek A., Mazurkiewicz-Pisarek A. et al. Mast cells as a target - a comprehensive review ofrecent therapeutic approaches. Cells. 2023; 12 (8): 1187.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Wilcock A., Bahri R., Bulfone-Paus S., Arkwright P. D. Mast cell disorders: From infancy to maturity. Allergy. 2019: 74 (Issue 1): 53 63.</mixed-citation><mixed-citation xml:lang="en">Wilcock A., Bahri R., Bulfone-Paus S., Arkwright P. D. Mast cell disorders: From infancy to maturity. Allergy. 2019: 74 (Issue 1): 53 63.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Микрюкова Н. В., Калинина Н. М. Синдром активации тучных клеток: новое мировоззрение. Медицинская иммунология. Режим доступа: https://doi.org/10.15789/1563-0625-MCA-2662.</mixed-citation><mixed-citation xml:lang="en">Mikryukova N. V., Kalinina N. M. Mast cell activation syndrome: a new world view. Meditsinskaya immunologiya. Available at: https: // doi.org/10.15789/1563-0625-MCA-2662. [(in Russian)]</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
